- Home
- BTAI vs GOVX Comparison
BTAI vs GOVX Comparison
Compare BTAI & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- GOVX
- Stock Information
- Founded
- BTAI 2017
- GOVX 2001
- Country
- BTAI United States
- GOVX United States
- Employees
- BTAI N/A
- GOVX N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- GOVX Health Care
- Exchange
- BTAI Nasdaq
- GOVX Nasdaq
- Market Cap
- BTAI 8.3M
- GOVX 7.6M
- IPO Year
- BTAI 2018
- GOVX N/A
- Fundamental
- Price
- BTAI $1.81
- GOVX $0.79
- Analyst Decision
- BTAI Buy
- GOVX Strong Buy
- Analyst Count
- BTAI 5
- GOVX 4
- Target Price
- BTAI $34.80
- GOVX $10.50
- AVG Volume (30 Days)
- BTAI 325.6K
- GOVX 2.8M
- Earning Date
- BTAI 08-05-2025
- GOVX 07-28-2025
- Dividend Yield
- BTAI N/A
- GOVX N/A
- EPS Growth
- BTAI N/A
- GOVX N/A
- EPS
- BTAI N/A
- GOVX N/A
- Revenue
- BTAI $1,852,000.00
- GOVX $5,591,576.00
- Revenue This Year
- BTAI N/A
- GOVX N/A
- Revenue Next Year
- BTAI $362.49
- GOVX N/A
- P/E Ratio
- BTAI N/A
- GOVX N/A
- Revenue Growth
- BTAI 5.47
- GOVX N/A
- 52 Week Low
- BTAI $1.17
- GOVX $0.43
- 52 Week High
- BTAI $19.84
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- BTAI 48.12
- GOVX 49.37
- Support Level
- BTAI $1.70
- GOVX $0.60
- Resistance Level
- BTAI $2.00
- GOVX $0.88
- Average True Range (ATR)
- BTAI 0.15
- GOVX 0.08
- MACD
- BTAI -0.03
- GOVX 0.03
- Stochastic Oscillator
- BTAI 20.00
- GOVX 68.40
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.